The biopharmaceutical company, which recently received $106m in equity from Merck, has raised an additional $57.5m, taking its overall funding to almost $295m.

The US National Institutes of Health provides $3m to Minnesota to escalate the commercialisation of healthcare products.

Dundee spin-out M-Squared to partner St Andrews on laser deal to treat cancer and other conditions.

Healthcare system UPMC has invested an undisclosed amount in Health Fidelity, which provides healthcare data analysis technology.

The gene editing company, backed by investors including Pfizer, is set to raise almost double its initial target, after pricing a flotation of 5.5 million shares.

Diabetes treatment company Semma will use the funding, as well as a strategic partnership with Novartis, to move its programme through initial clinical trials.

The medical device maker has backed a series A round for InterVene, which hopes to treat a condition where veins are incapable of pumping enough blood to the heart.

Novartis, Eli Lilly and KBI Biopharma contributed the series A funding for Aeglea, which is developing amino acid-directed therapeutics.

Aeglea, which is working on treatments for metabolic diseases, has now raised $56m in just over a year, after closing a series B round co-led by Novartis and Eli Lilly.